このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management

2026年11月12日 更新者:The Collagen Co. - GLP-1 Users

This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12.

Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.

調査の概要

研究の種類

介入

入学 (推定)

40

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Nevada
      • Las Vegas、Nevada、アメリカ、89101
        • Citruslabs

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Adults aged 18-55 years at the time of enrollment.
  • Currently using a GLP-1 receptor agonist or dual-incretin medication for weight management (e.g., semaglutide, tirzepatide, liraglutide) for a minimum of 4 weeks at the time of enrollment, with a stable or documented dose (no dose change within the 4 weeks prior to enrollment).
  • Self-reported interest in supporting weight management, lean muscle maintenance, nutritional adequacy, or beauty-related benefits (e.g., skin, hair, nails) during GLP-1 therapy.
  • Willing and able to use Glow Shakes Premium Collagen Meal Replacement as a once-daily meal replacement (replacing a typical meal) for 12 consecutive weeks and to complete all questionnaire assessments and Withings smart scale body composition measurements at Baseline, Week 4, Week 8, and Week 12.
  • Willing and able to maintain current GLP-1 or dual-incretin medication dose throughout the study duration without planned dose adjustments (except in the event of a medically indicated change).
  • Willing to maintain current diet (except for the study product), exercise routine, and lifestyle habits for the duration of the 12-week study, without introducing any new supplements or products specifically targeting weight loss, appetite, or body composition.
  • In good general health.
  • Resides in the United States.

Exclusion Criteria:

  • Pregnant or breastfeeding at the time of enrollment, or planning to become pregnant during the 12-week study period.
  • Known allergy or intolerance to any ingredient in the Glow Shakes formulation, including milk, whey, or collagen-derived ingredients.
  • Diagnosed with a serious medical condition requiring medical nutritional management, including but not limited to Type 1 diabetes, active cancer, or severe renal or hepatic disease.
  • Currently testing, or plan to in the next 12 weeks, a product for another research study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Glow Shakes Premium Collagen Meal Replacement Arm

Participants will consume one serving once daily - replacing a typical meal such as breakfast or lunch - for 12 consecutive weeks. One serving is prepared by adding the powder to 11.8 fl oz (approximately 350 mL) of water: add water first, then two scoops of powder, and shake for fewer than 10 seconds. Drink immediately after preparation.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Perceived Nutritional Adequacy
時間枠:Baseline to Week 12

Within-participant change in perceived nutritional adequacy assessed via self-report questionnaire

Baseline to Week 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Body Fat Percentage
時間枠:Baseline to Week 12

Within-participant change in body fat percentage (%) measured by participant self-administered Withings smart scale

Baseline to Week 12
Change in Muscle Mass
時間枠:Baseline to Week 12

Within-participant change in muscle mass (kg) measured by participant self-administered Withings smart scale

Baseline to Week 12
Change in Self-Reported Weight Management and Food Cravings
時間枠:Baseline to Week 12

Within-participant change assessed via the validated Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

Baseline to Week 12
Change in Self-Reported Perceived Skin Smoothness
時間枠:Baseline to Week 12

Within-participant change in perceived skin smoothness score assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Perceived Skin Elasticity
時間枠:Baseline to Week 12

Within-participant change in perceived skin elasticity score assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Hunger Intensity
時間枠:Baseline to Week 12

Within-participant change in perceived hunger intensity assessed via visual analogue scale or equivalent validated hunger/satiety instrument

Baseline to Week 12
Change in Self-Reported Satiety Duration
時間枠:Baseline to Week 12

Within-participant change in perceived satiety duration assessed via visual analogue scale or equivalent validated hunger/satiety instrument

Baseline to Week 12
Change in Self-Reported Food Craving Scores
時間枠:Baseline to Week 12

Within-participant change in food craving scores assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

Baseline to Week 12
Change in Self-Reported Hair Thickness
時間枠:Baseline to Week 12

Within-participant change in perceived hair thickness assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Hair Health
時間枠:Baseline to Week 12

Within-participant change in perceived hair health assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Energy Levels
時間枠:Baseline to Week 12

Within-participant change in perceived energy levels assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Cognitive Focus
時間枠:Baseline to Week 12

Within-participant change in perceived cognitive focus assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Nail Thickness
時間枠:Baseline to Week 12

Within-participant change in perceived nail thickness assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Nail Health
時間枠:Baseline to Week 12

Within-participant change in perceived nail health assessed via self-report questionnaire

Baseline to Week 12
Change in Gut Comfort and Digestive Health
時間枠:Baseline to Week 12

Within-participant change in gut comfort and digestive symptom scores assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Metabolism Support
時間枠:Baseline to Week 12

Within-participant change in perceived metabolism support assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Physical Strength
時間枠:Baseline to Week 12

Within-participant change in perceived physical strength assessed via self-report questionnaire

Baseline to Week 12
Product Tolerability and Participant Satisfaction
時間枠:Week 12

Participant-reported product satisfaction, acceptability, and tolerability assessed via product satisfaction questionnaire

Week 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2027年1月1日

研究の完了 (推定)

2027年1月1日

試験登録日

最初に提出

2026年11月12日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する